Skip to main content
Fig. 5 | BMC Medicine

Fig. 5

From: Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

Fig. 5

METscore forecasts survival outcomes of checkpoint blockade-based immunotherapy in the PD-L1-positive population. Kaplan-Meier curves showing overall survival according to METscore groups (≥ 3 vs. < 3) in A atezolizumab- and B docetaxel-treated populations from PD-L1-positive OAK cohort. Kaplan-Meier curves showing overall survival according to METscore groups in PD-L1-selected atezolizumab trials, C FIR and D BIRCH, and E NFyy cohort. Abbreviations: HR, hazard ratio; CI, confidence interval; PD-L1, programmed death-ligand 1

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us